Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pretty chart from early August up to today. It surely illustrates patience. Rarely do I have the patience to remain in that long. Congratulations.
TSRO
Out @ $34.25 -- chance to gain from small swing. Look to re-enter.
AAOI
Back in @ $33.10 due to early gap down.
Positive article today on Fool:
____________________________________________
Tariff Talk Sinks Applied Optoelectronics Stock Over 20%, but the Worry Is Overdone
Nicholas Rossolillo, The Motley Fool
Motley FoolSeptember 16, 2018
Shares of fiber optic networking manufacturer Applied Optoelectronics (NASDAQ: AAOI) fell as much as 25% in late August through early September on tariff worries. Comments from the White House that taxes could be imposed on virtually all goods imported into the U.S. from China sent investors scurrying for the exits, and Wall Street analyst downgrades of some of AOI's peers didn't help either. Since the company has operations in China, it could be argued that the political concerns are valid. However, AOI is in good shape, and after another stock price adjustment, shares look like a value play again.
Why some are concerned
At the beginning of September, President Trump warned he might tax another $267 billion in Chinese goods. After a couple of rounds of tariffs already imposed, that means virtually all goods imported to the U.S. from China would get hit with a tax.
Why is that bad news for Sugarland, Texas-based Applied Optoelectronics? Because AOI has three manufacturing facilities: one in Sugarland; one in Taipei, Taiwan; and a third in Ningbo, China. AOI spreads component manufacturing and different levels of its vertically integrated operations across all of its facilities, but the China factory plays a crucial role. The company explained it this way in its last annual report (emphasis is mine):
In our Sugar Land facility, we manufacture laser chips (utilizing our MBE and MOCVD process), subassemblies and components. The subassemblies are used in the manufacture of components by our other manufacturing facilities or sold to third parties as modules. We manufacture our laser chips only within our Sugar Land facility, where our laser design team is located. In our Taiwan location, we manufacture optical components, such as our butterfly lasers, which incorporate laser chips, subassemblies and components manufactured within our Sugar Land facility. In addition, in our Taiwan location, we manufacture transceivers for the internet data center, telecom, FTTH and other markets. In our China facility, we take advantage of lower labor costs and manufacture certain more labor intensive components and optical equipment systems, such as optical subassemblies and transceivers for the internet data center market, CATV transmitters (at the headend) and CATV outdoor equipment (at the node).
In addition, AOI is spending $90 million this year in capital expenditures, part of which includes a new facility in Ningbo, China, that recently broke ground and is expected to be completed in 2020. AOI doesn't say specifically how much of its manufacturing is done on mainland China, nor does it break down the specifics on the geographies in which its final product is sold. However, there is concern that any product that originates -- or has components that originate -- from China will get an extra tax, and that the extra cost will cause AOI to lose orders from its customers.
An illustration of a cloud representing a data center. Computers are arranged in a circle around the cloud, hooked up to it via the internet.
_________________________________________
https://finance.yahoo.com/news/tariff-talk-sinks-applied-optoelectronics-132100274.html
AAOI
Teucrium Corn Fund (CORN)
Another popular exchange-traded product that is used by active traders for trading movements in agriculture commodities is the Teucrium Corn Fund. Taking a look at the chart below, you can see that the price has failed to overcome the resistance of the 200-day moving average. This long-term moving average is considered to be even more significant than the 50-day moving average, as discussed above, and many bears will likely use it as a guide for placing their stop-loss orders. The lucrative risk/reward and bearish crossover between the MACD and its signal line are indications that the bears are in control, and short-term target prices will likely be placed near the July low of $15.66. (For further reading, see: The CORN ETF: The Best Way to Bet on Agriculture?)
Technical chart showing the performance of the Teucrium Corn Fund (CORN)
The Bottom Line
The bearish combination of fundamentals and technicals makes agricultural commodities of specific interest to active traders. Based on the charts above, traders will likely expect prices of major commodities such as corn and soybeans to head lower and will use nearby trendlines to set the placement of their orders. (For further reading, check out: A Primer for Investing in Agriculture.)
Charts courtesy of StockCharts.com. At the time of writing, Casey Murphy did not own a position in any of the securities mentioned.
_________________________________________________________
https://www.investopedia.com/news/3-charts-suggest-agriculture-commodities-could-move-lower/?partner=YahooSA&yptr=yahoo
My charting using different indicators also is bearish so I'm waiting. Of course I hesitated on the last downturn and missed out!
CORN
EDIT, just noticed that Finviz posted this today, but was from 8-14-18, not 9-14-18
Out today @ $35.40. Up on no news, only an article. Will buy back when drops. Problem with the current position is the high % of shorts ("Short Float 49.45%")
AAOI
In @ $34.50. Big sell-off over last two days due to analyst's negative comments on 2 competitor companies. Hopefully should recover.
AAOI
Out DAKT earlier today @ $8.05. Too soon as has shown subsequent strength, probably due to overall market reversal. Look to re-enter on any big dip.
DAKT
Out @ $29.60. Had bought back@ $26.70. Seems to be one stock which holds true to charting. Respects RSI and trades accordingly. Will re-enter on major dip.
NCR
Back in @ $7.50. Solid company will go back up.
DAKT
Sold @ $22.40 near the EOD. Took profits -- who knows what the Trump drug prices tweet will be tomorrow?
LJPC
Dynavax Technologies: What Lies Ahead
Aug. 11, 2018 1:22 PM ET|17 comments | About: Dynavax Technologies Corporation (DVAX)
Bret Jensen
Today we revisit Dynavax Technologies after its recent Q2 results.
2018 looks like it will continue to be an inflection year with 2019 being a payoff year for the company and its shareholders.
We go through the details of that projection in the paragraphs below.
Members of my private investing community, The Biotech Forum, receive access to my breaking news coverage of this idea. Get started today >>
A clear conscience is the sure sign of a bad memory.” ? Mark Twain
Dynavax Technologies (DVAX) posted second quarter results on Monday. There were pretty much inline to my expectations. However, several followers have asked for a post-Q2 follow up on this small cap concern which we provide in the paragraphs below.
Company Overview:
Dynavax Technologies is a 'Tier 3' biotech concern based in Berkeley California. The company is focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (NYSEMKT:TLR) stimulation for various indications. It currently has one approved biologic on the market 'heplisav-b' on the market. This compound is an improved hepatitis B vaccine that was approved by the FDA late in 2017. The stock currently has a market capitalization of just over $800 million and trades at around $13.50 a share.
(click link below for charts/images)
Source: Company Website
Second Quarter Highlights:
Heplisav-B sales only came in at $1.3 million for the quarter after doing $200,000 in revenue in Q1. More importantly, the company is making progress getting into coverage plans. Here is the company's statement about that in their press release as a percent of 'lives' heplisav-B is now covered for
'100% of Medicare-insured lives, 94% of commercially-insured lives, and 73% of lives under state Medicaid plans are covered'
Expectations Going Forward:
I saw some notes from William Blair earlier this week post the second quarter results from Dynavax. Blair's analyst is expecting roughly $15 million in Heplisav-B in FY2018 as the company is in the beginning of the sale channel for this vaccine. However, she expects the company to hit her break even projection of a $75 million to $80 million annual run rate by the end of 2019. She continues to expect heplisav-b to eventually have peak sales of $600 million. I have similar expectations.
Analyst Commentary & Balance Sheet:
The day after Q2 results, Cantor Fitzgerald raised their price target to $30 on DVAX from $27 previously. Here is the commentary behind that call
We are reiterating our Overweight rating and raising our 12- month PT to $30/share from $27/share, following 2Q18 financial results. Dynavax held a conference call to discuss financial and corporate updates. We believe there are a number of opportunities in the near future for Dynavax that could lead to upside for the company, including future HEPLISAV-B vaccine sales and a Phase 3 trial initiation on the horizon for SD-101 in advanced melanoma.”
Cantor's price target is now right at the median analyst bogey on this firm currently. The company ended the second quarter with cash and marketable securities of $216. million with another $75 million available from the February 2018 term loan agreement. R&D and SG&A costs totaled $32 million in the second quarter. The company seems to have no near or medium term funding needs at this time.
Verdict:
As I have commented on all year, 2018 is an inflection year for Dynavax and its shareholders as it begins the slow roll out of Heplisav-B and advances SD-101 in studies. 2019 is likely to be the payoff year for the company and its stakeholders.
Heplisav-B sales should start to show a significant upramp in 2019. In addition, a key Phase 3 SD-101 trial around low-grade, B cell lymphoma should initiate before the end of this year. The stock has been weak over the past month (as have most 'Tier 3' biotech stocks) after trading in the ~$15 to ~$21 range throughout 2018 before this recent weakness.
Accumulating shares here looks attractive given upcoming catalysts and I expect the stock to be trading in its previous 2018 range by the time Q3 results are reported.
Option Strategy:Image result for Stock Purchase
A alternative way to accumulate an initial stake or add to existing holdings in DVAX is via a Buy-Write order. Using the January $15 call strikes, fashion a Buy-Write order with a net debit in the $11.50 to $11.60 range (net stock price - option premium). This mitigates some downside risk and sets up a more than solid potential return for its just over five month hold period.
Wrong does not cease to be wrong because the majority share in it.” ? Leo Tolstoy, A Confession
Author's Note: To get these types of articles and Instablogs on attractive biotech and pharma stocks as soon as they are published, just click here for my profile. Hit the big orange "Follow" button and choose the real-time alerts option.
Disclosure: I am/we are long DVAX.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
_______________________________________________-
https://seekingalpha.com/article/4198025-dynavax-technologies-lies-ahead
DVAX
Out @ $29.60. Will watch for dip as there is more run-up left.
NCR
Out for small gain @ $6.10 -- apparently too soon.
Didn't want to be in for earnings tonite.
BLCM
Sold near EOD @ $35.26 for sizable loss, but glad I decided to sell. Stock was a big disappointment, analysts be dammed. They need to change their far to bullish analyses. Suppose will after the earnings call.
TSRO
Sold near EOD @ $59.60. Earnings pre-market tomorrow. Don't know the company that well and seems to have a mixed earnings record.
Good luck to longs.
BPMC
Approved according to FDA website.
PGNX
Out near the EOD @ $7.60. Was in for the run-up which was spoiled by a poor Bio day.
Good luck to anyone long. Potential is great.
PGNX
Maybe associated with the reversal today (together with the bio reversal):
_____________________________________________
3 Stocks That Could Double Your Money
[Motley Fool]
Cory Renauer, The Motley Fool
Motley FoolJuly 26, 2018
It isn't that hard to double your money if you're patient. If you had sunk money into an ETF that tracks the S&P 500 at the beginning of 2013, you would already have accomplished this feat without risking much in the process.
Developing new drugs to treat severe diseases can lead to overnight riches, and losses. These three biotech stocks could double impatient investors' money in the not so distant future if those investors don't mind accepting a great deal of risk. Here's how these three fledgling drugmakers will try to make it happen for their shareholders.
Progenics Pharmaceuticals, Inc.: Relieving pressure
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) is eagerly awaiting an approval decision that the FDA is expected to hand down by the end of July. Investors are a little nervous because the agency delayed Azedra's decision earlier this year to allow for a late addition of some non-critical information.
If approved, Azedra would become the first available treatment for two rare forms of cancer that affect the adrenal glands and often cause sky-high blood pressure. During a trial underpinning Azedra's application, patients were able to control their blood pressure with less help from other drugs. More importantly, patients that were treated with two doses survived more than twice as long as those given a single dose.
Pills on top of cash.
Right now, Progenics sports a modest $558 million market cap that could double if Azedra eventually becomes standard care for patients with pheochromocytoma and paraganglioma. If approved, gaining popularity could take some time, which Progenics has plenty of.
Why this one's my favorite
Geron and Galectin could double, but they could also get pounded flat if their lead candidates suffer any mishaps. Progenics, though, can depend on a modest revenue stream from Relistor, plus it has a prostate cancer imaging agent entering late-stage development. Relistor's a drug for opioid-induced constipation that doesn't exactly make ends meet for Progenics, but it has limited the company's losses to $48 million over the past year.
Progenics finished March with around $87 million in cash, and Azedra's aimed at a small, but highly motivated population. If this small biotech needs to tap investors for more capital to launch it successfully, it probably won't need much.
_____________________________________________
https://finance.yahoo.com/news/3-stocks-could-double-money-125700832.html?soc_src=social-sh&soc_trk=tw
PGNX
Highest short interest in 1 year:
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
7/13/2018 11,011,114 762,636 14.438230
_____________________________________________________-
https://www.nasdaq.com/symbol/pgnx/short-interest
Out @ $1.85 for sizable loss, minimized today. Not a stock to trade when you don't have a off market hours trading account. Twice recently watched pre-market sizable jumps dwindle.
CHFS
Close to 2nd support level:
Pivot Point 1st Resistance Point 8.27
8.22 14-3 Day Raw Stochastic at 50%
8.20 38.2% Retracement From 4 Week High
8.16 Price Crosses 9 Day Moving Average Stalls
8.11 38.2% Retracement From 13 Week High
8.08 50% Retracement From 4 Week High/Low
High 8.06 High
8.06 14-3 Day Raw Stochastic at 30%
8.04 Pivot Point
7.98 14-3 Day Raw Stochastic at 20%
Previous Close 7.96 Previous Close
7.95 38.2% Retracement From 4 Week Low
7.80 50% Retracement From 13 Week High/Low
7.78 3-10 Day MACD Oscillator Stalls
Pivot Point 1st Support Point 7.74
1-Month Low 7.55
Last 7.54 Last
Low 7.53 Low
7.52 Price Crosses 40 Day Moving Average Stalls
Pivot Point 2nd Support Point 7.51
7.49 38.2% Retracement From 13 Week Low
___________________________________________________
https://www.barchart.com/stocks/quotes/PGNX/cheat-sheet
PGNX
In @ $7.75. Thought it was a gift but has gone down to $7.57.
First time holding in a long time. Hoping for a bounce leading up to the catalyst.
PGNX
Back in @ $63.00. Chart not great.
BarChart cheat sheet:
Pivot Point 1st Resistance Point 65.67
65.43 50% Retracement From 4 Week High/Low
65.17 Price Crosses 18 Day Moving Average
64.70 Pivot Point
64.47 14-3 Day Raw Stochastic at 50%
64.05 38.2% Retracement From 4 Week Low
High 63.79 High
Previous Close 63.76 Previous Close
Last 63.11 Last
Pivot Point 1st Support Point 62.78
Low 62.69 Low
62.51 14-3 Day Raw Stochastic at 30%
62.46 3-10 Day MACD Oscillator Stalls
Pivot Point 2nd Support Point 61.81
________________________________________________
https://www.barchart.com/stocks/quotes/BPMC/cheat-sheet
BPMC
Nice beat. Will be interesting to see how it plays out as the analysts weigh in. It has been beating regularly but Wall Street seems to always want more. https://www.marketbeat.com/stocks/NYSE/IBM/earnings/
I'm on the sideline because I'm with a broker that doesn't have off-hours trading and the downside risk seemed more than the upside. Other than the period at the end of last January, for the past year whenever the RSI hits or is in over-bought territory a big downtrend begins.
IBM
Earnings after close. Sold @ $144.25 for small profit. Don't want to be in for earnings. Tried to sell 4 days ago when was over-bought, but was asking too much. Follows over- bought/sold chart closely.
IBM
Out @ $5.70 for small gain. Took advantage of the ATM announcement which normally would not be positive to sell. Look to buy back if/when it dips.
TRIL
Not in, but wish would have bought several weeks ago when it dipped below $54.
I see Baker Bros picked up more shares, but now 2nd to Seattle Genetics in their portfolio.
You must of had a good run.
INCY
Still sitting on $15.70 bid. Getting close (bid $15.78). Chart not good at all -- not sure I want them.
CORN
Glad out, in one trade just lost ~7.5% and now a days worth of volume is @ 2.50 ask.
SNOA
Out @ $2.70 after sitting on this ask for about a week. Could never sell although came close. With the wide spread the MMs would take it down to the LOD or near it in the last several minutes.
SNOA
FWIW:
Corn Faces Bullish And Bearish Factors
Jul. 9, 2018 6:30 AM ET|3 comments | About: Teucrium Corn ETF (CORN)
Andrew Hecht
Commodities, long/short equity, medium-term horizon, long-term horizon
MARKETPLACEHecht Commodity Report
(15,402 followers)
Summary
Corn has declined to the lowest price since 2017.
Tariffs weigh on all grains.
Energy is supportive.
Demographics point higher.
The weather will be the final arbiter for the price.
This idea was discussed in more depth with members of my private investing community, Hecht Commodity Report.
The trade issues facing the United States and its trading partners around the world have hit the grain markets harder than most other raw materials. While the other commodities in the crosshairs of the protectionist measures have experienced increased price volatility, the United States is the world’s leading producer and exporter of soybeans and corn. Therefore, retaliatory measures by China and other trading partners around the world have hit the U.S. right in the corn and bean belt. For farmers, the price action has amounted to a below the belt blow in a match that has not yet played out to a conclusion.
At a time of the year where uncertainty about the weather and size of the 2018 crop over the coming two months that are the heart of the growing season should be keeping prices stable, they have plunged. When it comes to the trade issue, China and other U.S. trading partners have decided to hit back striking at the heartland of the country with a long history as an agricultural nation. Despite tariffs, there are bullish and bearish factors present in the corn futures market these days. The most bearish factor has been trade and the resulting price action that has gripped corn futures since late May.
Corn had declined to the lowest price since 2017
While soybeans fell to the lowest level in a decade, the reaction in the corn market has been less dramatic.
Click link below for chart/tables
Source: CQG
As the weekly chart highlights, the price of nearby corn futures on the CBOT dropped to lows of $3.37 per bushel at the start of July which is the lowest price since December 2017 when they traded to a previous low at $3.3525. At just over $3.50 on the nearby futures contract on July 6, price momentum on the weekly chart displays a bearish trend that is falling towards oversold territory. A rally on Friday caused the daily chart to cross higher in oversold territory, while the monthly momentum crossed to the downside in neutral territory as a result of the selling in June. The long-term quarterly chart has not yet crossed lower, but and further selling could turn the long-term pictorial to the downside.
The price of corn has experience selling pressure at a time of the year when the 2018 crop is still not a sure thing. It will be the weather over the coming weeks that determines the final crop yield this year, but trade issues have trumped the weather and sent the price of corn to the lowest level of 2018. In a sell the rumor and buy the fact reaction to tariffs which took effect on Friday, the price of corn rallied on the final session of last week.
Tariffs weigh on all grains
While tariffs have weighed on the price of corn, it caused the price of soybeans to plunge.
Click link below for chart/tables
Source: CQG
Corn may be trading at the lowest price in almost seven months, but beans are at a decade low. As the monthly chart of nearby CBOT soybean futures demonstrates, the oilseed fell to a low of $8.34 per bushel over recent sessions which is the lowest price since December 2008 when it found a bottom at $7.77625. The December 2008 low is the current level of technical support for beans as the tariffs went into effect on China on July 6. China purchased one-quarter of the annual U.S. crop of the oilseed, so the trade issue and retaliation have weighed heavily on the price of bean futures. The U.S. is the world’s leading producer and exporter of both soybeans and corn, but the beans do not have support from another demand vertical that underpins the price of corn these days. Like corn, soybeans rallied significantly on Friday, the day that the tariffs took effect.
Energy is supportive
In the United States, corn is the primary ingredient in the production of ethanol. The ethanol mandate requires a blend of the corn-based biofuel and oil-based gasoline. The booming economy in the U.S., despite the current trade issues, has caused oil and gasoline prices to rise throughout 2018.
Click link below for chart/tables
Source: CQG
As the weekly chart of NYMEX gasoline futures shows, the fuel has been in a bull market making higher lows and higher highs since early February 2016. The most recent peak in the price of gasoline came at the end of May when the price reached $2.2855 per gallon wholesale. However, after a correction took the price of the fuel to a low that was just below $2 per gallon, gasoline recovered and was trading at just under the $2.1100 level at the end of last week.
Higher gasoline prices tend to support the price of ethanol. However, over past years, an oversupply of corn countered the impact of gasoline prices and the price of the biofuel has been stable.
Click link below for chart/tables
Source: CQG
As the weekly chart of ethanol futures shows, the range from early 2016 has been from lows of $1.251 to highs of $1.76 per gallon. At the $1.436 level at the end of last week on the nearby futures contract. At around seven cents below the midpoint of the trading range, the price of ethanol remains weak compared to gasoline, but it continues to provide demand for corn.
Click link below for chart/tables
Source: CQG
The premium of gasoline over ethanol prices has grown from a discount for gasoline when oil hit lows of $26.05 per barrel and gasoline prices were briefly under the 90 cents per gallon level in early 2016 to a premium of over 67 cents per gallon these days. While ethanol prices are at their lowest level versus gasoline since way back in 2014, the biofuel continues to provide a steady stream of demand for the corn market and keep prices from following soybeans lower into the bearish abyss over trade.
Demographics point higher
Trade issues aside, demographics continue to be supportive of all agricultural commodities. In Q2 the world added another 19-plus million mouths to feed. At the turn of this century, there were approximately six billion inhabitants of the planet and today that number stands at 7.484 billion. Each day, more people, with more financial resources, are competing for limited food and fuel resources which is a consistently rising demand factor for commodities like corn.
Click link below for chart/tables
Source: CQG
As the annual chart of corn prices dating back to 1968 shows, the price of the grain has been making higher lows over the period. Moreover, during times when drought caused a decline in output of the grain, the price has moved to higher highs. The last drought hit the corn market in 2012 and took the price to a record level at $8.4375 per bushel. During that year, soybean futures moved to just shy of $18 per bushel. Both grains are significantly below half those lofty levels these days, but both have seen demographic factors increase their lows over past decades.
In the world of agricultural commodities, demand factors like demographics tend to have a long-term impact on prices. However, short-term issues that weigh on demand or supplies can cause price shocks to the up or downside. Trade issues that could cause demand for U.S. corn (and beans) to drop over coming months have sent prices to lows. However, the supply side of the fundamental equation, which tends to be the most explosive at times, is still a matter of conjecture for the 2018 crop year.
The weather will be the final arbiter for the price
It is the beginning of July and corn crops are growing across the fertile plains of the United States. This year, because of high soybean prices before the planting season, farmers planted more beans than corn. Additionally, the USDA in their mon their monthly WASDE reports told markets that acreage for crops was lower this year than last.
Time will tell if the weather over the coming weeks will support crop production or drought conditions will limit output during the harvest season in the fall. However, less corn planting and fewer acres allocated to the grain promise that after five consecutive years of bumper crops in the U.S., 2018 may not be the sixth. There is still a lot of the 2018 growing season left, and despite trade issues, a weather event that limits crop yields this year could turn the recent implosive price action explosive.
The overriding sentiment in the corn market this year is bearish given the devastating potential impact of tariffs and retaliation on demand. However, the world requires food which transcends the political issues surrounding trade. Any shortage of corn could propel the price higher at a time when it is trading at the lowest level of the year, and energy prices are providing consistent support.
The most direct route for an investment or trade on the long side in the corn market is via the futures and options on futures offered by the CBOT division of the Chicago Mercantile Exchange. For those who do not venture into the highly leveraged and volatile world of futures, the CORN ETF product has net assets of over $73 million and trades over 100,000 shares on an average trading session. CORN holds three CBOT corn futures contracts and does an excellent job reflecting the price action in the futures market for the grain.
Corn is facing bullish and bearish factors these days. Energy prices and rising global demand for food are supportive, while trade has been weighing on the price of the grain. At the lowest price of the year, and with all of the negative news associated with tariffs and retaliation weighing on the price of corn, the grain is close to its lowest price of the year. It is possible that the next surprise in the corn market comes on the upside since the bearish news is on the front pages of the news cycle while the supportive factors continue to limit the downside potential for the price of corn.
The Hecht Commodity Report is one of the most comprehensive commodities reports available today from the #2 ranked author in both commodities and precious metals. My weekly report covers the market movements of 20 different commodities and provides bullish, bearish and neutral calls; directional trading recommendations, and actionable ideas for traders. More than 120 subscribers are deriving real value from the Hecht Commodity Report.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: The author always has positions in commodities markets in futures, options, ETF/ETN products, and commodity equities. These long and short positions tend to change on an intraday basis.
___________________________________________________
https://seekingalpha.com/article/4185901-corn-faces-bullish-bearish-factors?app=1
CORN
Guess we got the answer today. Suppose sub $16 is gone.
CORN
Out @ $67.80. Has moved nicely with biotech of late. Moving to greater resistance. Will be back.
BPMC
Have a bid @ $15.70. Probably won't get it, but low bid in case it falls and a few stops are taken out. Maybe will do the same on Thursday at opening.
Pure chart play as still don't understand the tariff implications. Seems that soy beans are the crop of concern?
CORN